BI-1206
Phase 2Biologic
BI-1206 is one of 3 biologic programs targeting B-cell NHL. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in B-Cell NHL
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 2
Calquence
AstraZenecaPhase 2
BI-1206
BBioInvent International AB
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BI-1206. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- BBioInvent International AB